Mark Neumann - 10 Mar 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP, Chief Commercial Officer
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
14 Mar 2022, 16:13:45 UTC
Previous filing
25 Feb 2022
Next filing
08 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Award $0 +17,916 $0.000000 17,916 10 Mar 2022 Common Stock 17,916 $56.73 Direct F1
transaction ITCI Restricted Stock Units Award $0 +22,034 $0.000000 22,034 10 Mar 2022 Common Stock 22,034 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 10, 2022, the reporting person was granted options to purchase 17,916 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.